Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01065012 · ClinicalTrials.gov registry record · Phase 3
Treatment of Erectile Dysfunction - Long Term Safety and Efficacy
A Phase 3 study, sponsored by Warner Chilcott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,027
- Enrollment target
NCT01065012: Completed Phase 3 study, sponsored by Warner Chilcott.
NCT01065012 is a Phase 3 study that has completed, run by Warner Chilcott. The registered enrollment target is 1,027 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01065012, a Phase 3 study, has completed, sponsored by Warner Chilcott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,027 participants
- Enrollment target
Study Summary
Open-Label Phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of PDE-5 for the treatment of subjects with erectile dysfunction (ED).
Interventions
- DRUG Udenafil 50 mg
- DRUG Udenafil 100 mg
- DRUG Udenafil 150 mg
- DRUG Placebo Matching 50 mg Udenafil
- DRUG Placebo Matching 100 mg Udenafil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,027 participants |
| Start Date | 2010-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
What the finished NCT01065012 record still lists
NCT01065012 is an interventional study that assigns participants to a tested intervention. Its 1,027 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% higher).
The record links to 0 conditions, and to 5 interventions - of which Udenafil 50 mg is the first listed.
NCT01065012 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01065012 about?
NCT01065012 is a clinical study titled "Treatment of Erectile Dysfunction - Long Term Safety and Efficacy". Open-Label Phase 3 study to evaluate the long-term safety and efficacy of udenafil, an orally administered selective inhibitor of PDE-5 for the treatment of subjects with erectile dysfunction (ED).
What is the current status of trial NCT01065012?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,027 participants. The study started on 2010-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01065012?
The interventions under investigation include: Udenafil 50 mg (DRUG), Udenafil 100 mg (DRUG), Udenafil 150 mg (DRUG), Placebo Matching 50 mg Udenafil (DRUG), Placebo Matching 100 mg Udenafil (DRUG).
Who is sponsoring clinical trial NCT01065012?
This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01065012's enrollment target sits among peer trials
1,027 288th of 2000 higher than 1,713 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02200276 · 1,025 participants · NA
Influenza Immunization in Adults Over Age 75
- NCT02296450 · 1,025 participants
Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments
- NCT06080698 · 1,030 participants · NA
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
- NCT06888011 · 1,024 participants · NA
iAmHealthy Clinical Practice Guideline (CPG)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia